Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
The FDA has accepted the New Drug Application for pimicotinib, an investigational CSF-1R) inhibitor, for the treatment of patients with symptomatic tenosynovial giant cell tumor.
The FDA has accepted the New Drug Application for pimicotinib, an investigational CSF-1R) inhibitor, for the treatment of patients with symptomatic tenosynovial giant cell tumor.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
